Serological survey


Select item(s)
Key Findings
In 19205 participants, the seroprevalence was <3% until Mid-December 2020 in all regions. Mostly low seroprevalence was estimated in Reutlingen, Aachen, Freiburg, and Osnabrück after the first wave while serological study in Magdeburg cumulatively already indicates the onset of the second wave.
PMID
Title SARS-CoV-2 seroprevalence in Germany - a population based sequential study in five regions
Author(s) nameManuela Harries
Journal
Impact factor
Citation count
Date of publishing2021 May 6
Serological survey of mild/asymptomatic SARS-CoV-2 infected individuals were tested with three immunoassays. Antibodies were found to be present for atleast 8 months after infection.
PMID
Title Serological survey of mild/asymptomatic SARS-CoV-2 infected individuals were tested with three immunoassays. Antibodies were found to be present for atleast 8 months after infection.
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
Serological survey of mild/asymptomatic SARS-CoV-2 infected individuals were tested with three immunoassays. Antibodies were found to be present for atleast 8 months after infection.
PMID
Title Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
Out of 30 COVID-19 patients, 23 showed the presence of anti-N antibodies, 20 showed anti-S** antibodies, and 13 had anti-M antibodies.
PMID 33330866
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ, Ai Y, Li M, Pekosz A, Cox A, Atai N, Gould SJ.
Journal bioRxiv
Impact factorIts not a journal
Citation count1
Date of publishing2020 Dec 9
Out of 10,449 Healthcare professionals, 136 showed seropositivity with 70% presenting with symptoms, including Cough (23.2%), Headache (22.1%) and Fatigue (21.1%).
PMID 33292895
Title Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic
Author(s) nameRosser JI, Röltgen K, Dymock M, Shepard J, Martin A, Hogan CA, Blomkalns A, Mathew R, Parsonnet J, Pinsky BA, Maldonado YA, Boyd SD, Chang SI, Holubar M; Stanford Healthcare COVID-19 Workforce Response Group.
Journal Infect Control Hosp Epidemiol
Impact factor2.66
Citation count1
Date of publishing2020 Dec 9
Out of 1686 individuals in Germany, 46 (2.7%) were seropositive for anti-SARS-CoV-2 IgG antibodies.
PMID 33339986
Title Rheumatic disease and COVID-19: epidemiology and outcomes
Author(s) nameHyrich KL, Machado PM.
Journal Nat Rev Rheumatol
Impact factor
Citation count2
Date of publishing2020 Dec 18
Out of 790 participants in an University student population, estimated seroprevalence of Anti-SARS-CoV-2 IgG antibodies was 4%. This indicated that the prevalence of infection/SARS-COV-2 antibodies in a University population was similar to the community seroprevalence.
PMID 33071164
Title A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population
Author(s) nameTilley K, Ayvazyan V, Martinez L, Nanda N, Kawaguchi ES, O'Gorman M, Conti D, Gauderman WJ, Van Orman S.
Journal J Adolesc Health
Impact factor
Citation count1
Date of publishing2020 Dec
Out of 7361 individuals in Netherlands, 200 (2.7%) were seropositive. Antibodies were more significantly detected in younger people of 18-30 years age group (4.2%) compared to older people of 61-72 years age group (2.7%).
PMID 33184284
Title Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
Author(s) nameSlot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, IJlst J, NovotnĂ˝ VMJ, van Lier RAW, Zaaijer HL.
Journal Nat Commun
Impact factor11.8
Citation count2
Date of publishing2020 Nov 12
Out of 1122 participants in an Indian Tertiary care hospital, overall seroprevalence for SARS-CoV-2 IgG antibodies was 11.94% of which 19.85% of High risk healthcare workers, 11.09% of Intermediate risk Healthcare workers and 8% of Low risk healthcare workers were seropositive .
PMID 33187030
Title Seroprevalence of COVID-19 amongst Health care workers in a Tertiary Care Hospital of a Metropolitan City from India
Author(s) nameGoenka M, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, Shah BB, Patil VU, Rodge G, Khan U, Bandyopadhyay S.
Journal J Assoc Physicians India
Impact factor
Citation count2
Date of publishing2020 Nov
Among the healthworkers under study, majority were seronegative indicating lack of antibodies to SARS-CoV-2.
PMID 33033249
Title SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden
Author(s) nameRudberg AS, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, Gabrielsson L, Salomonsson AC, Hanke L, Murrell B, McInerney G, Olofsson J, Andersson E, Hellström C, Bayati S, Bergström S, Pin E, Sjöberg R, Tegel H, Hedhammar M, Phillipson M, Nilsson P, Hober S, Thålin C.
Journal Nat Commun
Impact factor11.8
Citation count11
Date of publishing2020 Oct 8
Out of 1215 recovered persons and 4222 quarantined persons,1107 (91.1%) and 97 (2.3%) were seropositive, repectively.
PMID 32871063
Title Humoral Immune Response to SARS-CoV-2 in Iceland
Author(s) nameGudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B, Kristjansdottir S, Birgisdottir K, Kristinsdottir AM, Sigurdsson MI, Arnadottir GA, Ivarsdottir EV, Andresdottir M, Jonsson F, Agustsdottir AB, Berglund J, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Gottfredsson M, Gretarsdottir OS, Gudmundsdottir S, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Helgason A, Jensson BO, Jonasdottir A, Jonsson H, Kristjansson T, Kristinsson KG, Magnusdottir DN, Magnusson OT, Olafsdottir LB, Rognvaldsson S, le Roux L, Sigmundsdottir G, Sigurdsson A, Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B, Thordardottir M, Saemundsdottir J, Kristjansson SH, Josefsdottir KS, Masson G, Georgsson G, Kristjansson M, Moller A, Palsson R, Gudnason T, Thorsteinsdottir U, Jonsdottir I, Sulem P, Stefansson K.
Journal N Engl J Med
Impact factor37.91
Citation count80
Date of publishing2020 Oct 29
Seroconversion of SARS-CoV-2 in people living with HIV (PLWH) on stable ART occurred similarly to that in non-HIV-infected patients.
PMID 33046418
Title Antibody response to SARS-CoV-2 in people living with HIV.
Author(s) nameYamamoto S, Saito M, Nagai E, Toriuchi K, Nagai H, Yotsuyanagi H, Nakagama Y, Kido Y, Adachi E.
Journal J Microbiol Immunol Infect
Impact factor2.33
Citation count1
Date of publishing2020 Oct 2
Out of 291 participants in long term facilities, including 122 residents and 169 staff, 113 were sero-reactive and 178 were non-reactive.
PMID 33086096
Title Serological survey following SARS-COV-2 outbreaks at long term care facilities in netro Vancouver, British Columbia: Implications for outbreak management and infection control policies
Author(s) nameVijh R, Ghafari C, Hayden A, Schwandt M, Sekirov I, Morshed M, Levett P, Krajden M, Boraston S, Daly P, Lysyshyn M, Harding J, McLennan M, Chahil N, Mak A, McKee G.
Journal Am J Infect Control
Impact factor2.03
Citation count1
Date of publishing2020 Oct 18
Out of 5391 participants, a seropositivity rate of 61.2% for IgM, 58.8% for IgG and 62.1% for IgM/IgG in COVID-19 confirmed cases, seropositivity rate of 29% for IgM, 37% for IgG, 55% for both IgM/IgG in suspected cases and 19% for IgM/IgG in asymptomatic cases were observed.
PMID 33090430
Title Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies
Author(s) nameGuo CC, Mi JQ, Nie H.
Journal Eur Rev Med Pharmacol Sci
Impact factor2.51
Citation count1
Date of publishing2020 Oct
Out of 464 healthcare workers, 809 industrial employees and 402 community members in Karachi, Pakistan, 13%, 50.3% and 34%, were seropositive respectively. Overall seroprevalence rate was 36%.
PMID 32940328
Title Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi - Challenges in acquiring herd immunity for COVID-19
Author(s) nameZaidi S, Rizwan F, Riaz Q, Siddiqui A, Khawaja S, Imam M, Naz A, Waheed S, Shamsi T.
Journal J Public Health (Oxf)
Impact factor1.55
Citation count1
Date of publishing2020 Sep 17
Out of 51958 participants in Spain, overall seroprevalence rate was 4.6% using Chemiluminescence immunoassay. Out of 4.6%, patients with positive PCR status greater than 14 days showed 90.1% seroprevalence rate.
PMID 32645347
Title Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Author(s) namePollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, Fernández de Larrea N, Molina M, Rodríguez-Cabrera F, Martín M, Merino-Amador P, León Paniagua J, Muñoz-Montalvo JF, Blanco F, Yotti R; ENE-COVID Study Group.
Journal Lancet
Impact factor43.38
Citation count198
Date of publishing2020 Aug 22
Out of 61075 participants in Spain, overall seroprevalence rate was 5% using Point rapid care testing. Out of 5% ,patients with positive PCR status greater than 14 days showed 88.6% seroprevalence rate.
PMID 32645347
Title Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Author(s) namePollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, Fernández de Larrea N, Molina M, Rodríguez-Cabrera F, Martín M, Merino-Amador P, León Paniagua J, Muñoz-Montalvo JF, Blanco F, Yotti R; ENE-COVID Study Group.
Journal Lancet
Impact factor43.38
Citation count198
Date of publishing2020 Aug 22
Seroprevalence estimates for 5 weeks did not show much difference after 1st week of the study.
PMID 32534626
Title Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Author(s) nameStringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, GĂ©taz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I.
Journal Lancet
Impact factor43.38
Citation count119
Date of publishing2020 Aug 1
Out of 17368 participants, cumulative seroprevalence of IgM and IgG was reported as 44% and 56%, respectively.
PMID 32504052
Title Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Author(s) nameXu X, Sun J, Nie S, Li H, Kong Y, Liang M, Hou J, Huang X, Li D, Ma T, Peng J, Gao S, Shao Y, Zhu H, Lau JY, Wang G, Xie C, Jiang L, Huang A, Yang Z, Zhang K, Hou FF.
Journal Nat Med
Impact factor22.66
Citation count48
Date of publishing2020 Aug
Out of 1293 parturient women in Philadelphia, 80 (6.2%) had IgG and/or IgM SARS-CoV-2specific antibodies. The seropositivity was higher in Black/non-Hispanic and Hispanic/Latino women compared to Asian and White/non-Hispanic women.
PMID 32727884
Title SARS-CoV-2 seroprevalence among parturient women in Philadelphia
Author(s) nameFlannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, Gerber JS, Arevalo CP, Bolton MJ, Weirick ME, Goodwin EC, Anderson EM, Greenplate AR, Kim J, Han N, Pattekar A, Dougherty J, Kuthuru O, Mathew D, Baxter AE, Vella LA, Weaver J, Verma A, Leite R, Morris JS, Rader DJ, Elovitz MA, Wherry EJ, Puopolo KM, Hensley SE.
Journal Sci Immunol
Impact factor8.16
Citation count19
Date of publishing2020 Jul 29
Out of 1914 serum samples from 35 species of animals, none of them were seropositive.
PMID 32303108
Title Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals
Author(s) nameDeng J, Jin Y, Liu Y, Sun J, Hao L, Bai J, Huang T, Lin D, Jin Y, Tian K.
Journal Transbound Emerg Dis
Impact factor3.47
Citation count23
Date of publishing2020 Jul
Out of 1071 samples, 41 samples were SARS-CoV-2 IgG positive with a proportion of 3.83%, including 4.8% in central metropolitan Tokyo, 1.6% in suburban Tokyo and the highest 7.92% in the southern areas of central Tokyo.
PMID 32674696
Title Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care ClinicBased Point-of-Care Antibody Testing
Author(s) nameTakita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, Kusumi E.
Journal J Prim Care Community Health
Impact factor
Citation count3
Date of publishing2020 Jan-Dec
Out of 1071 patient samples in Tokyo, 41 (3.83%) samples were SARS-CoV-2 IgG positive including a seroprevalence rate of 4.8% in Central metropolitan Tokyo, 1.6% in suburban Tokyo and the highest rate of 7.92% in the southern areas of central Tokyo.
PMID 32674696
Title Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing
Author(s) nameTakita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, Kusumi E.
Journal J Prim Care Community Health
Impact factor
Citation count3
Date of publishing2020 Jan-Dec
Out of 200 children in Prague, 2 were seropositive (<0.5%) which was comparatively lesser than overall seroprevalence (1.3%).
PMID 33304869
Title Searching for COVID-19 Antibodies in Czech ChildrenA Needle in the Haystack
Author(s) nameBloomfield M, Pospisilova I, Cabelova T, Sediva A, Ibrahimova M, Borecka K, Magner M.
Journal Front Pediatr
Impact factor2.46
Citation count1
Date of publishing2020
Out of 2906 individuals tested for SARS-CoV-2 IgG antibodies, 111 (3.8%) were seropositive. 14 (10.4%) out of 135 symptomatic and 97 (3.5%) out of 2771 asymptomatic patients were IgG seropositive.
PMID 33175878
Title Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - A cross- sectional study
Author(s) nameKhan SMS, Qurieshi MA, Haq I, Majid S, Bhat AA, Nabi S, Ganai NA, Zahoor N, Nisar A, Chowdri IN, Qazi TB, Kousar R, Lone AA, Sabah I, Nabi S, Sumji IA, Kawoosa MF, Ayoub S.
Journal PLoS One
Impact factor2.87
Citation count1
Date of publishing2020